Find the best CNRS technologies to boost your innovative project.
06.11.2018
Materials – Coating 07293-01
06.11.2018
Materials – Coating 10581-01
06.11.2018
Chemistry / Environment 08758-01
06.11.2018
11127-01
06.11.2018
Environment and Energy 11107-01
19.10.2018
Medical Diagnostic 08504-01
We can guide you through the whole technology transfer process.
Thanks to our expertise, our network and our know-how of the innovation ecosystem, we support you throughout your project.
05433-01
Down’s syndrome, Alzheimer’s disease, Kinase inhibitors, CNS
French priority patent application n° FR 12 62275 filed on December 18, 2012
WO2014096093
Robert H. DODD
Jean DELABAR
Kevin CARIOU
Stéphanie GOURDAIN
Nathalie JANEL
Fernando RODRIGUES-LIMA
Julien DAIROU
Clément DEHNEZ
Exclusive or non-exclusive licenses
Institut de Chimie des Substances Naturelles (ICSN), UPR2301, CNRS, Gif-sur-Yvette, France
Down’s Syndrome (DS) is the most common genetic disorder with a frequency of 1 in 700 live births worldwide, and it is associated with an increased risk of Alzheimer’s disease. DYRK1A is considered a pathogenic factor in DS and has been implicated in the abnormal hyperphosphorylation of tau protein in Alzheimer’s disease brain.
The inventors have designed new azaindole-based DYRK1A inhibitors that demonstrate potent activity against DYRK1A and high affinity for the ATP-binding site. In vitro evaluation and computer-guided molecular design were used to select the appropriate candidates. No cytotoxicity has been detected, and primary data obtained on wild-type and DS model mice are very promising. For example, recent studies show that 2 weeks treatment with the new DYRK1A inhibitor was sufficient to improve the performances of DS mice model (Ts65Dn) in the Morris Water Maze.
This work is financially supported by the programme “Emergence of high potential products or services” of the Agence Nationale pour la Recherche.
Development of DANDYs, new 3,5-diaryl-7-azaindoles demonstrating potent DYRK1A kinase inhibitory activity.
Gourdain S, Dairou J, Denhez C, Bui LC, Rodrigues-Lima F, Janel N, Delabar JM, Cariou K, Dodd RH.
J Med Chem. 2013 Dec 12;56(23):9569-85
For further information, please contact us (Ref 05433-01)
31.03.2015
Health / Therapeutic, Medical Diagnostic 06081-01
10.03.2014
Health / Therapeutic, Other Technologies 00017-04
03.03.2014
Health / Therapeutic 03946-01
06.11.2018
Materials – Coating 07293-01
06.11.2018
Materials – Coating 10581-01
06.11.2018
Chemistry / Environment 08758-01
06.11.2018
11127-01
06.11.2018
Environment and Energy 11107-01
19.10.2018
Medical Diagnostic 08504-01